Opendata, web and dolomites

Mind-Gap SIGNED

Bridging the treatment gap for mild and moderate anxiety and depression across EU

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "Mind-Gap" data sheet

The following table provides information about the project.

Coordinator
EXPLORABLE AS 

Organization address
address: SODAL TERRASSE 44
city: KRISTIANSAND
postcode: 4630
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Norway [NO]
 Project website http://elp.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-09-01   to  2019-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EXPLORABLE AS NO (KRISTIANSAND) coordinator 50˙000.00

Map

 Project objective

Each year, 25% of the EU population suffer from depression or anxiety, with higher rates for women than men. The cost of mood disorders and anxiety in the EU is about €170 billion per year. In most of the EU countries, patients with mild and moderate anxiety and depression only get access to specialised treatment from mental health professionals when the illness become severe. In the future, the society will have major problems in providing good healthcare if we are not able prevent more: between 1990-2013 the number of people suffering from depression and/or anxiety increased by nearly 50%. Experts emphasize that Internet-assisted treatments based on Cognitive Behavioural Therapy (ICBTs) have a great potential to improve care for mental disorders, but current solutions are having a slow adoption by health providers, mental health professionals and patients because they are very generic, do not provide controls to guarantee medical effectiveness and/or have not been designed to be used by health providers. Explorable AS has developed the unique ICBT marketplace specially designed to be directly used by health providers. It includes an authoring tool so that practitioners at these health providers can easily create their owned ICBTs by implementing engaging technologies and gamified concepts. ICBTs will also be available to other practitioners working at other health providers. Patients only get access to ICBTs in our marketplace under the prescription of general or mental health practitioners: in that way we guarantee that patients get ICBTs with proven evidence-based therapies or best-practice methods, and they get access to specialised treatment designed by mental health professionals from the onset of their illness. The overall objective of Mind-Gap Phase 1 is to carry out a feasibility study to verify the technological, practical and economic viability of scaling up our platform to other EU countries (market replication).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MIND-GAP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MIND-GAP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Woodywood pickering (2019)

Bio-based (fully renewable) cost effective Polymer for new generation of ecological Coatings leveraging a disruptive innovation in the use of Pickering emulsion.

Read More  

NAAS (2019)

NaaS - Newsroom as a service

Read More  

SA-VOIR (2019)

Assessing the feasibility of MT-011, a first-in-class drug to treat glaucoma and other neurodegenerative diseases via a breakthrough mechanism-of-action

Read More